Justin E. Bekelman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Justin E. Bekelman has a total of 141 co-authors. Here are the top co-authors by number of shared publications:
John Paul Christodouleas
University of Pennsylvania, Philadelphia, PA
6 shared publicationsKatrina Armstrong
Massachusetts General Hospital, Boston, MA
6 shared publicationsStephen M. Hahn
MD Anderson Cancer Center, Houston, TX
6 shared publications- Andrew J. Epstein
Department of Veterans Affairs' Center for Health Equity Research and Promotion, Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania
4 shared publications Ezekiel J. Emanuel
Department of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia
4 shared publicationsNandita Mitra
University of Pennsylvania, Philadelphia, PA
4 shared publications
Latest Publications
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e18048
A multidimensional view of racial differences in access to prostate cancer care.
E18048 Background: Racial differences in prostate cancer treatment and outcomes are widespread and poorly understood. We sought to determine whether access to care, measured across multiple dimensions, contribute to racial differences in prostate cancer. Methods: The Philadelphia Area Prostate Cancer Access Study (P2 Access) included 2374 men diagnosed with localized prostate cancer from 2012 to 2014. Patient survey data was used to determine experiences of accessing prostate cancer care (response rate 51.1%). An audit survey using simulated patient calls was used to determine appointment availability and wait times at 151 urology practices. Patient and practice addresses were geocoded to construct distance measures. We used multivariable logistic regression models to determine the association between five different domains of access—availability, accessibility, accommodation, affordability, and acceptability—and receipt of definitive treatment with radical prostatectomy or radiation, satisfaction with care, and doctor-patient communication. Results: There were 1907 non-Hispanic white and 394 black men in our cohort, the majority (71%) with stage 1 disease. Overall, 85% of men received definitive treatment with no differences by race. None of the access domains were significantly associated with definitive treatment overall or with radical prostatectomy in adjusted models. Black men were less likely to report good doctor-patient communication (60% vs 71%, p < 0.001) and high satisfaction with their care (69% vs 81%, p < 0.001). Communication ratings remained significantly lower among black men compared to white men in adjusted models (odds ratio = 1.49, 95% Confidence Interval 1.03, 2.16). Each domain of access was significantly associated with lower satisfaction with care and worse communication; however, differences in access did not mediate racial disparities for these measures. Conclusions: This study presents the first comprehensive assessment of access to prostate cancer care, showing that while access was related to overall satisfaction and better doctor-patient communication, it did not appear to explain racial differences in these measures of cancer care.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e18048
A multidimensional view of racial differences in access to prostate cancer care.
E18048 Background: Racial differences in prostate cancer treatment and outcomes are widespread and poorly understood. We sought to determine whether access to care, measured across multiple dimensions, contribute to racial differences in prostate cancer. Methods: The Philadelphia Area Prostate Cancer Access Study (P2 Access) included 2374 men diagnosed with localized prostate cancer from 2012 to 2014. Patient survey data was used to determine experiences of accessing prostate cancer care (response rate 51.1%). An audit survey using simulated patient calls was used to determine appointment availability and wait times at 151 urology practices. Patient and practice addresses were geocoded to construct distance measures. We used multivariable logistic regression models to determine the association between five different domains of access—availability, accessibility, accommodation, affordability, and acceptability—and receipt of definitive treatment with radical prostatectomy or radiation, satisfaction with care, and doctor-patient communication. Results: There were 1907 non-Hispanic white and 394 black men in our cohort, the majority (71%) with stage 1 disease. Overall, 85% of men received definitive treatment with no differences by race. None of the access domains were significantly associated with definitive treatment overall or with radical prostatectomy in adjusted models. Black men were less likely to report good doctor-patient communication (60% vs 71%, p < 0.001) and high satisfaction with their care (69% vs 81%, p < 0.001). Communication ratings remained significantly lower among black men compared to white men in adjusted models (odds ratio = 1.49, 95% Confidence Interval 1.03, 2.16). Each domain of access was significantly associated with lower satisfaction with care and worse communication; however, differences in access did not mediate racial disparities for these measures. Conclusions: This study presents the first comprehensive assessment of access to prostate cancer care, showing that while access was related to overall satisfaction and better doctor-patient communication, it did not appear to explain racial differences in these measures of cancer care.
- 1 March 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 97 (4) , 718-721
Six Questions to Ask Before We Shorten Radiation Treatments for Intact Prostate Cancer
- 1 March 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 97 (4) , 718-721
Six Questions to Ask Before We Shorten Radiation Treatments for Intact Prostate Cancer
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e16617
Phase I trial of everolimus plus radiation therapy for salvage treatment of biochemical recurrence in prostate cancer patients following prostatectomy.
E16617 Background: Up to half of patients treated with salvage radiation therapy (RT) for rising PSA ultimately develop a second biochemical recurrence (sBCR). Phosphatase and tensin homolog inactivation is implicated in prostate cancer progression, and upregulation of the mammalian target of rapamycin (mTOR) pathway can lead to tumor hypoxia and radioresistance. Everolimus is an mTOR inhibitor with both anti-tumor and radiosensitizing effects. Methods: We performed an investigator-initiated phase I study using a modified 3+3 dose-escalation design to evaluate the safety and tolerability of everolimus in combination with standard salvage RT for the treatment of BCR following prostatectomy. After a two-week run-in period of everolimus daily therapy, patients received prostate bed irradiation (15 IMRT, 1 proton) with daily cone beam CT localization in 37 fractions of 1.8 Gy each (total dose 66.6 Gy). Patients were monitored for both acute ( ≤ 90 days) and chronic ( > 90 days) treatment-related toxicities. sBCR was defined as a rise in PSA of > 0.5 ng/ml above nadir following the completion of protocol therapy. Results: 16 patients received everolimus at dose levels of 5 mg (dose level 1), 7.5 mg, or 10 mg daily in conjunction with RT. One patient withdrew consent after 7 days of everolimus and is unevaluable for follow-up. No dose-limiting toxicities were observed. The most common acute treatment related toxicities included: Grade 1/2 mucositis (63%), Grade 1/2 fatigue (44%), Grade 1/2 rash (56%), and Grade 1 urinary symptoms (63%). Three patients (19%) experienced a Grade 3 acute toxicity (N = 1 for rash, anemia, and neutropenia), and no patients experienced Grade ≥ 3 chronic toxicity. After a median follow-up time of 20.1 months, five patients (33%) developed sBCR. The median time to sBCR was 33.8 months (IQR 20.1 – 46.0 months). Conclusions: Everolimus at a dose of ≤ 10 mg daily appears to be safe and tolerable in combination with fractionated post-prostatectomy RT. As everolimus has anti-tumor efficacy in a variety of solid tumor malignancies, the use of everolimus with RT could be safely considered for further investigation in multiple solid tumors. Clinical trial information: NCT01548807.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e16617
Phase I trial of everolimus plus radiation therapy for salvage treatment of biochemical recurrence in prostate cancer patients following prostatectomy.
E16617 Background: Up to half of patients treated with salvage radiation therapy (RT) for rising PSA ultimately develop a second biochemical recurrence (sBCR). Phosphatase and tensin homolog inactivation is implicated in prostate cancer progression, and upregulation of the mammalian target of rapamycin (mTOR) pathway can lead to tumor hypoxia and radioresistance. Everolimus is an mTOR inhibitor with both anti-tumor and radiosensitizing effects. Methods: We performed an investigator-initiated phase I study using a modified 3+3 dose-escalation design to evaluate the safety and tolerability of everolimus in combination with standard salvage RT for the treatment of BCR following prostatectomy. After a two-week run-in period of everolimus daily therapy, patients received prostate bed irradiation (15 IMRT, 1 proton) with daily cone beam CT localization in 37 fractions of 1.8 Gy each (total dose 66.6 Gy). Patients were monitored for both acute ( ≤ 90 days) and chronic ( > 90 days) treatment-related toxicities. sBCR was defined as a rise in PSA of > 0.5 ng/ml above nadir following the completion of protocol therapy. Results: 16 patients received everolimus at dose levels of 5 mg (dose level 1), 7.5 mg, or 10 mg daily in conjunction with RT. One patient withdrew consent after 7 days of everolimus and is unevaluable for follow-up. No dose-limiting toxicities were observed. The most common acute treatment related toxicities included: Grade 1/2 mucositis (63%), Grade 1/2 fatigue (44%), Grade 1/2 rash (56%), and Grade 1 urinary symptoms (63%). Three patients (19%) experienced a Grade 3 acute toxicity (N = 1 for rash, anemia, and neutropenia), and no patients experienced Grade ≥ 3 chronic toxicity. After a median follow-up time of 20.1 months, five patients (33%) developed sBCR. The median time to sBCR was 33.8 months (IQR 20.1 – 46.0 months). Conclusions: Everolimus at a dose of ≤ 10 mg daily appears to be safe and tolerable in combination with fractionated post-prostatectomy RT. As everolimus has anti-tumor efficacy in a variety of solid tumor malignancies, the use of everolimus with RT could be safely considered for further investigation in multiple solid tumors. Clinical trial information: NCT01548807.
- 20 January 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (3_suppl) , 91
Understanding the impact of primary care providers on treatment decisions for men with localized prostate cancer.
91 Background: Primary care providers (PCPs) play important roles for cancer patients across the care continuum and may help patients make treatment decisions in line with patients’ preferences. However, the extent of PCP involvement is poorly understood. We evaluated how frequently men with localized prostate cancer discuss treatment with their PCP and whether PCP involvement decreased use of definitive treatment, including among those eligible for surveillance according to clinical guidelines. Methods: We mailed surveys to men diagnosed with localized prostate cancer between 2012 and 2013 in the greater Philadelphia area. Patients reporting having a PCP at the time of diagnosis were asked whether their PCP helped decide how to treat their cancer. Definitive treatment was defined as having radical prostatectomy or radiation therapy. Unadjusted and multivariate logistic regression analyses were used to compare sociodemographic and clinical characteristics of patients who did and did not discuss treatment with their PCP. Similar analyses were used to determine effect of PCP involvement on definitive treatment, both overall and in subgroups of men eligible for surveillance (men > 70 years, with limited life expectancy and with low-risk prostate cancer). Results: 3743 men were mailed a survey, 1757 responded, and 1139 were eligible for analyses. Overall, 438 (38.5%) discussed treatment with their PCP. In adjusted analyses, black men were more likely than white men (Odds Ratio 1.89; 95% Confidence Interval 1.22-2.91) and men with Medicare were more likely than men with private insurance (OR 1.61; 95% CI 1.03-2.51) to discuss treatment with their PCP. However, men who had treatment discussions with their PCP were not less likely to receive definitive treatment (p = 0.11), both overall and among those eligible for surveillance. Conclusions: Though a large proportion of men engaged in treatment discussions with their PCP, these discussions were not associated with differences in the receipt of definitive treatment among men with localized prostate cancer. Understanding the content of these discussions can inform interventions that can help patients make preference concordant treatment decisions.
- 20 January 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (3_suppl) , 91
Understanding the impact of primary care providers on treatment decisions for men with localized prostate cancer.
91 Background: Primary care providers (PCPs) play important roles for cancer patients across the care continuum and may help patients make treatment decisions in line with patients’ preferences. However, the extent of PCP involvement is poorly understood. We evaluated how frequently men with localized prostate cancer discuss treatment with their PCP and whether PCP involvement decreased use of definitive treatment, including among those eligible for surveillance according to clinical guidelines. Methods: We mailed surveys to men diagnosed with localized prostate cancer between 2012 and 2013 in the greater Philadelphia area. Patients reporting having a PCP at the time of diagnosis were asked whether their PCP helped decide how to treat their cancer. Definitive treatment was defined as having radical prostatectomy or radiation therapy. Unadjusted and multivariate logistic regression analyses were used to compare sociodemographic and clinical characteristics of patients who did and did not discuss treatment with their PCP. Similar analyses were used to determine effect of PCP involvement on definitive treatment, both overall and in subgroups of men eligible for surveillance (men > 70 years, with limited life expectancy and with low-risk prostate cancer). Results: 3743 men were mailed a survey, 1757 responded, and 1139 were eligible for analyses. Overall, 438 (38.5%) discussed treatment with their PCP. In adjusted analyses, black men were more likely than white men (Odds Ratio 1.89; 95% Confidence Interval 1.22-2.91) and men with Medicare were more likely than men with private insurance (OR 1.61; 95% CI 1.03-2.51) to discuss treatment with their PCP. However, men who had treatment discussions with their PCP were not less likely to receive definitive treatment (p = 0.11), both overall and among those eligible for surveillance. Conclusions: Though a large proportion of men engaged in treatment discussions with their PCP, these discussions were not associated with differences in the receipt of definitive treatment among men with localized prostate cancer. Understanding the content of these discussions can inform interventions that can help patients make preference concordant treatment decisions.
- 1 September 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (25) , 2833
Reply to G. Gandaglia et al and K. Lu
- 1 September 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (25) , 2833
Reply to G. Gandaglia et al and K. Lu
- 1 March 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (7_suppl) , 111
Contemporary trends in receipt of local therapy for men with clinically localized high-risk prostate cancer.
111 Background: Level I evidence suggests local treatment results in improved survival as compared to androgen deprivation therapy (ADT) alone or watchful waiting for high risk prostate cancer (CaP), but contemporary trends in primary treatment for high risk CaP are poorly understood. Our aim is to examine local therapy utilization for patients with high risk CaP using a large national cancer registry. Methods: Using the National Cancer Database (NCDB), patients with clinically localized CaP meeting National Comprehensive Cancer Network high risk criteria were identified from 2004-2009. Men with node positive or metastatic disease were excluded. Adjusting for diagnosis year and demographic we examined the association between patient characteristics and local therapy, defined as radical prostatectomy (RP) or radiation (RT), in men with high risk CaP using logistic regression models. Results: A total of 132,369 men met inclusion criteria with 80% receiving local therapy and 12% receiving no treatment. There was a small but significant increase in local therapy utilization from 2004-2009 (79 to 81%, p70 years (OR 0.27, CI 0.23-0.30) or Charlson morbidity count > 2 (OR 0.43, CI 0.39-0.46) were less likely to receive local therapy. Further, men of African American race (OR 0.7, CI 0.67-0.74) and Medicare (OR 0.82, CI 0.77-0.87) or Medicaid (OR 0.6, 0.53-0.68) insurance were less likely to receive primary treatment than Caucasian patients or those with private insurance. Conclusions: In the NCDB, 80% of men presenting with clinically localized high risk CaP undergo local therapy as part of multimodality treatment or as monotherapy, with RP overtaking RT+ADT as the primary local treatment of choice. Furthermore, racial and insurance disparities in the receipt of primary treatment are still evident, providing targets for emerging CaP quality of care initiatives.
- 1 March 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (7_suppl) , 111
Contemporary trends in receipt of local therapy for men with clinically localized high-risk prostate cancer.
111 Background: Level I evidence suggests local treatment results in improved survival as compared to androgen deprivation therapy (ADT) alone or watchful waiting for high risk prostate cancer (CaP), but contemporary trends in primary treatment for high risk CaP are poorly understood. Our aim is to examine local therapy utilization for patients with high risk CaP using a large national cancer registry. Methods: Using the National Cancer Database (NCDB), patients with clinically localized CaP meeting National Comprehensive Cancer Network high risk criteria were identified from 2004-2009. Men with node positive or metastatic disease were excluded. Adjusting for diagnosis year and demographic we examined the association between patient characteristics and local therapy, defined as radical prostatectomy (RP) or radiation (RT), in men with high risk CaP using logistic regression models. Results: A total of 132,369 men met inclusion criteria with 80% receiving local therapy and 12% receiving no treatment. There was a small but significant increase in local therapy utilization from 2004-2009 (79 to 81%, p70 years (OR 0.27, CI 0.23-0.30) or Charlson morbidity count > 2 (OR 0.43, CI 0.39-0.46) were less likely to receive local therapy. Further, men of African American race (OR 0.7, CI 0.67-0.74) and Medicare (OR 0.82, CI 0.77-0.87) or Medicaid (OR 0.6, 0.53-0.68) insurance were less likely to receive primary treatment than Caucasian patients or those with private insurance. Conclusions: In the NCDB, 80% of men presenting with clinically localized high risk CaP undergo local therapy as part of multimodality treatment or as monotherapy, with RP overtaking RT+ADT as the primary local treatment of choice. Furthermore, racial and insurance disparities in the receipt of primary treatment are still evident, providing targets for emerging CaP quality of care initiatives.
- 1 March 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (7_suppl) , 347
Validating a local failure risk stratification for use in a prospective study of adjuvant radiation in bladder cancer.
347 Background: To inform the design of trials of adjuvant radiation (RT) for bladder cancer, a local failure (LF) risk grouping has been proposed and externally validated that stratifies radical cystectomy (RC) pts into 3 groups based on pathologic factors. This stratification was developed using historical surgical databases and may not reflect outcomes in the observation arm of a modern trial. The purpose of the study is to assess whether trial accrual bias or improving surgical techniques over time impact the validity of the stratification or reduce the LF risk estimates for each subgroup. Methods: The LF stratification was developed using 2 cohorts treated with RC +/- chemo: a single-institution cohort of 442 pts (1990-2008) and the multi-center SWOG 8710 cohort of 264 pts (1987-1998). To assess the impact of trial accrual bias, we excluded pts who developed LF, DM, died, or were lost to follow up
- 1 March 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (7_suppl) , 347
Validating a local failure risk stratification for use in a prospective study of adjuvant radiation in bladder cancer.
347 Background: To inform the design of trials of adjuvant radiation (RT) for bladder cancer, a local failure (LF) risk grouping has been proposed and externally validated that stratifies radical cystectomy (RC) pts into 3 groups based on pathologic factors. This stratification was developed using historical surgical databases and may not reflect outcomes in the observation arm of a modern trial. The purpose of the study is to assess whether trial accrual bias or improving surgical techniques over time impact the validity of the stratification or reduce the LF risk estimates for each subgroup. Methods: The LF stratification was developed using 2 cohorts treated with RC +/- chemo: a single-institution cohort of 442 pts (1990-2008) and the multi-center SWOG 8710 cohort of 264 pts (1987-1998). To assess the impact of trial accrual bias, we excluded pts who developed LF, DM, died, or were lost to follow up
- 1 March 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (7_suppl) , 28
Impact of dose-escalated radiation on overall survival in men with nonmetastatic prostate cancer.
28 Background: Infive publishedRCTs, dose-escalated external beam radiation therapy (EBRT) for prostate cancer resulted in improved biochemical and local control. However, the question of whether dose escalation improves overall survival (OS) remains unanswered. We examined OS among men with non-metastatic prostate cancer undergoing EBRT in the modern era. Methods: Using the National Cancer Database (NCDB), we conducted non-randomized comparative effectiveness studies of dose-escalated versus standard-dose EBRT in men diagnosed from 2004-2006 in three analytic cohorts defined by NCCN risk category: low- (N=12,848), intermediate- (N=14,966) or high-risk (N=14,587) prostate cancer. We categorized patients in each risk cohort into 2 treatment groups: standard-dose (68.4 Gy to
- 1 March 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (7_suppl) , 28
Impact of dose-escalated radiation on overall survival in men with nonmetastatic prostate cancer.
28 Background: Infive publishedRCTs, dose-escalated external beam radiation therapy (EBRT) for prostate cancer resulted in improved biochemical and local control. However, the question of whether dose escalation improves overall survival (OS) remains unanswered. We examined OS among men with non-metastatic prostate cancer undergoing EBRT in the modern era. Methods: Using the National Cancer Database (NCDB), we conducted non-randomized comparative effectiveness studies of dose-escalated versus standard-dose EBRT in men diagnosed from 2004-2006 in three analytic cohorts defined by NCCN risk category: low- (N=12,848), intermediate- (N=14,966) or high-risk (N=14,587) prostate cancer. We categorized patients in each risk cohort into 2 treatment groups: standard-dose (68.4 Gy to
- 1 March 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (7_suppl) , 119
Disparities in baseline magnetic resonance imaging (MRI) utilization and imaging characteristics for prostate cancer (PCa) patients.
119 Background: Blacks with low risk PCa more likely to have adverse pathologic features at prostatectomy and larger dominant intraprostatic lesions (DIPL) with high anterior foci prevalence. Whether pretreatment MRI identifies these differences is unknown. The aim of this study was to determine whether disparities exist in MRI utilization and imaging characteristics for PCa patients. Methods: An institutional database of 617 PCa patients treated with proton and/or intensity modulated radiotherapy from 2005-2013 identified patients with pelvic MRI (T2 weighted, diffusion weighted, and/or dynamic contrast-enhanced sequences, 91% with endorectal coil). DIPL presence, size, extracapsular extension (ECE) and seminal vesicle invasion (SVI) were reviewed. Whites vs. Blacks overall and stratified by risk group were compared using Fishers exact test for categorical and student’s t-test for continuous variables (P2(vs 295 ± 285; P=0.042), with no differences in DIPL presence, additional IPLs, ECE, or SVI. Conclusions: In this urban, academic center cohort, Black PCa patients were significantly less likely to undergo staging MRI. No differences were found in DIPL presence, area, ECE, or SVI, except in the high-risk group. Further investigation is required to better understand how pretreatment MRI utilization and imaging characteristics differ by race.
- 1 March 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (7_suppl) , 119
Disparities in baseline magnetic resonance imaging (MRI) utilization and imaging characteristics for prostate cancer (PCa) patients.
119 Background: Blacks with low risk PCa more likely to have adverse pathologic features at prostatectomy and larger dominant intraprostatic lesions (DIPL) with high anterior foci prevalence. Whether pretreatment MRI identifies these differences is unknown. The aim of this study was to determine whether disparities exist in MRI utilization and imaging characteristics for PCa patients. Methods: An institutional database of 617 PCa patients treated with proton and/or intensity modulated radiotherapy from 2005-2013 identified patients with pelvic MRI (T2 weighted, diffusion weighted, and/or dynamic contrast-enhanced sequences, 91% with endorectal coil). DIPL presence, size, extracapsular extension (ECE) and seminal vesicle invasion (SVI) were reviewed. Whites vs. Blacks overall and stratified by risk group were compared using Fishers exact test for categorical and student’s t-test for continuous variables (P2(vs 295 ± 285; P=0.042), with no differences in DIPL presence, additional IPLs, ECE, or SVI. Conclusions: In this urban, academic center cohort, Black PCa patients were significantly less likely to undergo staging MRI. No differences were found in DIPL presence, area, ECE, or SVI, except in the high-risk group. Further investigation is required to better understand how pretreatment MRI utilization and imaging characteristics differ by race.
- 1 March 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (7) , 716-722
Effectiveness of Androgen-Deprivation Therapy and Radiotherapy for Older Men With Locally Advanced Prostate Cancer
Purpose: We examined whether the survival advantage of androgen-deprivation therapy with radiotherapy (ADT plus RT) relative to ADT alone for men with locally advanced prostate cancer reported in two randomized trials holds in real-world clinical practice and extended the evidence to patients poorly represented in the trials. Methods: We conducted nonrandomized effectiveness studies of ADT plus RT versus ADT in three groups of patients diagnosed between 1995 and 2007 and observed through 2009 in the SEER-Medicare data set: (1) the randomized clinical trial (RCT) cohort, which included men age 65 to 75 years and was most consistent with participants in the randomized trials; (2) the elderly cohort, which included men age > 75 years with locally advanced prostate cancer; and (3) the screen-detected cohort, which included men age ≥ 65 years with screen-detected high-risk prostate cancer. We evaluated cause-specific and all-cause mortality using propensity score, instrumental variable (IV), and sensitivity analyses. Results: In the RCT cohort, ADT plus RT was associated with reduced cause-specific and all-cause mortality relative to ADT alone (cause-specific propensity score–adjusted hazard ratio [HR], 0.43; 95% CI, 0.37 to 0.49; all-cause propensity score–adjusted HR, 0.63; 95% CI, 0.59 to 0.67). Effectiveness estimates for the RCT cohort were not significantly different from those from randomized trials (P > .1). In the elderly and screen-detected cohorts, ADT plus RT was also associated with reduced cause-specific and all-cause mortality. IV analyses produced estimates similar to those from propensity score–adjusted methods. Conclusion: Older men with locally advanced or screen-detected high-risk prostate cancer who receive ADT alone risk decrements in cause-specific and overall survival.
- 1 March 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (7) , 716-722
Effectiveness of Androgen-Deprivation Therapy and Radiotherapy for Older Men With Locally Advanced Prostate Cancer
Purpose: We examined whether the survival advantage of androgen-deprivation therapy with radiotherapy (ADT plus RT) relative to ADT alone for men with locally advanced prostate cancer reported in two randomized trials holds in real-world clinical practice and extended the evidence to patients poorly represented in the trials. Methods: We conducted nonrandomized effectiveness studies of ADT plus RT versus ADT in three groups of patients diagnosed between 1995 and 2007 and observed through 2009 in the SEER-Medicare data set: (1) the randomized clinical trial (RCT) cohort, which included men age 65 to 75 years and was most consistent with participants in the randomized trials; (2) the elderly cohort, which included men age > 75 years with locally advanced prostate cancer; and (3) the screen-detected cohort, which included men age ≥ 65 years with screen-detected high-risk prostate cancer. We evaluated cause-specific and all-cause mortality using propensity score, instrumental variable (IV), and sensitivity analyses. Results: In the RCT cohort, ADT plus RT was associated with reduced cause-specific and all-cause mortality relative to ADT alone (cause-specific propensity score–adjusted hazard ratio [HR], 0.43; 95% CI, 0.37 to 0.49; all-cause propensity score–adjusted HR, 0.63; 95% CI, 0.59 to 0.67). Effectiveness estimates for the RCT cohort were not significantly different from those from randomized trials (P > .1). In the elderly and screen-detected cohorts, ADT plus RT was also associated with reduced cause-specific and all-cause mortality. IV analyses produced estimates similar to those from propensity score–adjusted methods. Conclusion: Older men with locally advanced or screen-detected high-risk prostate cancer who receive ADT alone risk decrements in cause-specific and overall survival.